Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
An Alternative Dosing Schedule of Varenicline for Smoking Cessation
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00835900
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Long-term Varenicline Treatment for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 101
- Registration Number
- NCT00828113
- Locations
- 🇺🇸
Center for Tobacco Research and Intervention, Milwaukee, Wisconsin, United States
Varenicline for the Treatment of Smokeless Tobacco
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 76
- Registration Number
- NCT00813917
- Locations
- 🇺🇸
Nicotine Research Program, Rochester, Minnesota, United States
Varenicline in Bipolar Depressed Patients
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2012-01-30
- Lead Sponsor
- Mark Frye
- Target Recruit Count
- 11
- Registration Number
- NCT00813800
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1373
- Registration Number
- NCT00808015
- Locations
- 🇵🇭
Pfizer Investigational Site, Quezon City, Philippines
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 28
- Registration Number
- NCT00803868
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
- Conditions
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 93
- Registration Number
- NCT00802919
- Locations
- 🇺🇸
Manhattan Psychatirc Center, New York, New York, United States
🇺🇸Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States
🇨🇳Peking University Institute of Mental Health, Beijing, China
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 330
- Registration Number
- NCT00794365
Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Mark Eisenberg
- Target Recruit Count
- 302
- Registration Number
- NCT00794573
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦SMBD - Jewish General Hospital, Montreal, Quebec, Canada
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Butler Hospital
- Target Recruit Count
- 315
- Registration Number
- NCT00790569
- Locations
- 🇺🇸
Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.